Neurocrine Biosciences, Inc. today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results